JP2000344793A - Deprotection of oligonucleotides - Google Patents
Deprotection of oligonucleotidesInfo
- Publication number
- JP2000344793A JP2000344793A JP11154975A JP15497599A JP2000344793A JP 2000344793 A JP2000344793 A JP 2000344793A JP 11154975 A JP11154975 A JP 11154975A JP 15497599 A JP15497599 A JP 15497599A JP 2000344793 A JP2000344793 A JP 2000344793A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- protecting group
- oligonucleotide
- strong acid
- liquid chromatography
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 28
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title claims description 16
- 238000010511 deprotection reaction Methods 0.000 title abstract description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 23
- 125000006239 protecting group Chemical group 0.000 claims abstract description 21
- 239000002253 acid Substances 0.000 claims abstract description 18
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 9
- 238000004811 liquid chromatography Methods 0.000 claims abstract description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims abstract description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims abstract description 4
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000003480 eluent Substances 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 239000000243 solution Substances 0.000 abstract description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 abstract description 14
- 230000035484 reaction time Effects 0.000 abstract description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 abstract description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 abstract description 7
- -1 dimethoxytrityl Chemical group 0.000 abstract description 5
- 239000007864 aqueous solution Substances 0.000 abstract description 2
- 238000003379 elimination reaction Methods 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 31
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000001818 capillary gel electrophoresis Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000003835 nucleoside group Chemical class 0.000 description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- KMEMIMRPZGDOMG-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid Chemical compound NP(O)OCCC#N KMEMIMRPZGDOMG-UHFFFAOYSA-N 0.000 description 1
- VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- AVBGNFCMKJOFIN-UHFFFAOYSA-N triethylammonium acetate Chemical compound CC(O)=O.CCN(CC)CC AVBGNFCMKJOFIN-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Saccharide Compounds (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、水酸基が疎水性保
護基で保護されたオリゴヌクレオチド類を液体クロマト
グラフィーで精製した後、該オリゴヌクレオチド類を効
率的に脱保護する方法に関する。The present invention relates to a method for purifying oligonucleotides whose hydroxyl groups are protected with a hydrophobic protecting group by liquid chromatography, and then efficiently deprotecting the oligonucleotides.
【0002】[0002]
【従来の技術】DNAの合成は、昨今の自動合成機の普及
により簡単に行えるようになった。かかる合成機で一般
に用いられている合成法は、固相シアノエチルホスホア
ミダイト法であり、図1に示されるような合成サイクル
で表わされる。すなわち、まず、5′位の水酸基がジメ
トキシトリチル(DMTr)基で保護されたヌクレオシド
を、その3′位水酸基を介して、CPG(コントロールポ
アグラス)等の不溶性の担体にエステル結合させる(図
1[I])。そして、このヌクレオシドユニットの5′位
の水酸基を脱保護し(図1[II])、次に、触媒存在下、
次のヌクレオチドユニットのアミダイト体(図1[II
I])を縮合させる。このアミダイト体は、ヌクレオシド
の5′位の水酸基がDMTr基で保護され、3′位の水酸基
に3価のリンを備え、当該3価のリンには保護基として
β−シアノエチル基が結合し、脱離基としてジアルキル
アミノ基が結合している。かくして生成したジヌクレオ
チド(図1[IV])の3価のリンは、ヨウ素で5価に酸化
される(図1[V])。また、未反応の5′位の水酸基
は、アセチル化によりキャッピングすることで、以後の
伸長反応から排除される。そして、このサイクルを繰り
返すことにより、所望のDNAが合成される。2. Description of the Related Art DNA synthesis has become easier with the recent spread of automatic synthesizers. A synthesis method generally used in such a synthesizer is a solid-phase cyanoethyl phosphoramidite method, which is represented by a synthesis cycle as shown in FIG. That is, first, a nucleoside in which the 5′-hydroxyl group is protected with a dimethoxytrityl (DMTr) group is ester-bonded to an insoluble carrier such as CPG (control pore glass) via the 3′-hydroxyl group (FIG. 1). [I]). Then, the hydroxyl group at the 5'-position of this nucleoside unit is deprotected (FIG. 1 [II]).
The amidite form of the next nucleotide unit (Fig. 1 [II
I]). In this amidite form, the 5'-hydroxyl group of the nucleoside is protected with a DMTr group, and the 3'-hydroxyl group is provided with trivalent phosphorus, and a β-cyanoethyl group is bonded to the trivalent phosphorus as a protecting group, A dialkylamino group is bound as a leaving group. Trivalent phosphorus of the dinucleotide (FIG. 1 [IV]) thus produced is oxidized to pentavalent with iodine (FIG. 1 [V]). The unreacted hydroxyl group at the 5'-position is excluded from the subsequent extension reaction by capping by acetylation. Then, by repeating this cycle, a desired DNA is synthesized.
【0003】合成されたDNAは、濃アンモニア水により
担体から切り出されてバイアルに捕集され、これを60
℃で4〜5時間処理して、ヌクレオシドの塩基のアミノ
基の保護基とリンの保護基(β−シアノエチル基)とが
脱離される。その後、この粗オリゴDNAは、脱離された
前記保護基や縮合不良のオリゴDNAを含むため、逆相液
体クロマトグラフィー(逆相HPLC)法で精製され
る。目的のDNAは、脱離された保護基とは大きく分子量
が異なり、また、5′末端が疎水性のDMTr基で保護され
ているため、DMTr基を備えない縮合不良のオリゴDNAと
は疎水性の程度が異なることから、逆相HPLCで高純度に
精製できる。[0003] The synthesized DNA is cut out of the carrier with concentrated aqueous ammonia and collected in a vial.
By treating at 4 ° C. for 4 to 5 hours, the protecting group for the amino group of the base of the nucleoside and the protecting group for phosphorus (β-cyanoethyl group) are eliminated. Thereafter, the crude oligo DNA contains the above-mentioned eliminated protecting group and oligo DNA with poor condensation, and thus is purified by reverse phase liquid chromatography (reverse phase HPLC). The target DNA has a significantly different molecular weight from the removed protecting group, and since the 5 'end is protected by a hydrophobic DMTr group, it is hydrophobic with poorly condensed oligo DNA that does not have a DMTr group. Can be purified to high purity by reversed-phase HPLC.
【0004】[0004]
【発明が解決しようとする課題】上記の様にしてHPLC分
取された目的のオリゴDNAは、DMTr基を脱離(脱Tr化)
して最終製品とされる。このHPLC分取されたオリゴDNA
は、HPLCの溶離液中の溶液状態にあるため、従来は、減
圧乾燥により溶離液を除去して乾燥させた後、80%酢
酸を添加して30分間脱Tr化を行い、再度減圧乾燥して
酢酸を除去して再溶解させていた。The target oligo DNA obtained by HPLC fractionation as described above removes the DMTr group (elimination of Tr).
The final product. Oligo DNA separated by HPLC
Is in a solution state in the HPLC eluent, so that conventionally, the eluent was removed by drying under reduced pressure, dried, then detrified for 30 minutes by adding 80% acetic acid, and dried again under reduced pressure. The acetic acid was removed and redissolved.
【0005】かかる従来の脱Tr化法は、上述のように2
回の減圧乾燥・再溶解工程を要し、また、反応時間も3
0分程度要していた。また、アンチセンス核酸医薬研究
に用いられるホスホロチオエート型オリゴDNA(オリゴ
デオキシヌクレオチドホスホロチオエート)の場合は、
80%酢酸水溶液に溶解しにくいことがあり、脱Tr化反
応が不十分になることがあった。[0005] As described above, the conventional method for removing Tr has the following problems.
Times of vacuum drying and re-dissolving steps, and the reaction time is 3
It took about 0 minutes. In the case of phosphorothioate-type oligo DNA (oligodeoxynucleotide phosphorothioate) used for antisense nucleic acid drug research,
It may be difficult to dissolve in an 80% acetic acid aqueous solution, and the Tr removal reaction may be insufficient.
【0006】本発明は、液体クロマトグラフィー法によ
って精製されたオリゴヌクレオチド類の脱Tr化反応にお
いて、その工程を簡略化するとともにその工程日数を短
縮することを目的とする。[0006] It is an object of the present invention to simplify the steps and shorten the number of days of the steps in the deTr reaction of oligonucleotides purified by liquid chromatography.
【0007】[0007]
【課題を解決するための手段】本発明によれば、上記目
的は、水酸基が疎水性保護基で保護されたオリゴヌクレ
オチド類を含む液体クロマトグラフィーの溶離液中に強
酸を添加して、該オリゴヌクレオチド類の疎水性保護基
を脱離することを特徴とするオリゴヌクレオチドの脱保
護方法によって達成される。According to the present invention, the above object is achieved by adding a strong acid to an eluent for liquid chromatography containing an oligonucleotide whose hydroxyl group is protected by a hydrophobic protecting group. This is achieved by a method for deprotecting an oligonucleotide, which comprises removing a hydrophobic protecting group of nucleotides.
【0008】すなわち、本発明は、水酸基が疎水性保護
基で保護されたオリゴヌクレオチド類を、溶離液中に含
まれた状態のまま、強酸と反応させて該保護基を脱離さ
せることを特徴とするものであり、強酸を直接溶離液に
添加するだけで脱保護を行うことができるので、操作が
簡単である。さらに、HPLC分取された精製オリゴヌクレ
オチド類を、溶離液の減圧乾燥・再溶解工程を経ること
なく、分取された状態のまま脱保護できるので、オリゴ
ヌクレオチドの精製工程を簡略化でき、精製の手間と時
間が減少するので好都合である。That is, the present invention is characterized in that oligonucleotides having a hydroxyl group protected by a hydrophobic protecting group are reacted with a strong acid while being contained in an eluent to remove the protecting group. The deprotection can be performed only by adding the strong acid directly to the eluent, so that the operation is simple. Furthermore, since the purified oligonucleotides separated by HPLC can be deprotected as they are without being subjected to the step of drying and re-dissolving the eluent under reduced pressure, the oligonucleotide purification step can be simplified and the purification can be simplified. This is convenient because the labor and time of the operation are reduced.
【0009】本発明の脱保護方法は、オリゴヌクレオチ
ドであれば、いかなる種類のものにも適用できる。本発
明において、オリゴヌクレオチド類は、デオキシリボヌ
クレオチド及びリボヌクレオチド等のヌクレオチドを構
成単位とし、各ヌクレオチド間が糖の3′位と5′位炭
素のリン酸ジエステル結合で結ばれたものであり、天然
及び合成のDNA及びRNAの他、これらのリン酸部又はヌク
レオシド部が修飾されている修飾体をも包含する概念で
ある。リン酸部が修飾されたオリゴヌクレオチド類とし
ては、例えば、オリゴデオキシヌクレオチドホスホロチ
オエート(ホスホロチオエート型オリゴDNA)が挙げら
れる。合成オリゴヌクレオチド類は、公知のアミダイト
法及びリン酸トリエステル法に基づく方法によって得ら
れたものを包含する。疎水性保護基は、酸で容易に脱離
する保護基であれば限定されることはなく、代表的に
は、オリゴヌクレオチド類の5′末端の水酸基を保護す
るジメトキシトリチル(DMTr)基が挙げられる。[0009] The deprotection method of the present invention can be applied to any kind of oligonucleotide. In the present invention, oligonucleotides are composed of nucleotides such as deoxyribonucleotides and ribonucleotides as structural units, and each nucleotide is linked by a phosphodiester bond at the 3′- and 5′-carbons of the sugar. In addition to synthetic DNAs and RNAs, the term encompasses modified products in which the phosphate moiety or nucleoside moiety is modified. Oligonucleotides in which the phosphate moiety is modified include, for example, oligodeoxynucleotide phosphorothioate (phosphorothioate-type oligo DNA). Synthetic oligonucleotides include those obtained by methods based on the known amidite method and phosphotriester method. The hydrophobic protecting group is not limited as long as it is a protecting group which can be easily removed by an acid, and typically, a dimethoxytrityl (DMTr) group which protects a hydroxyl group at the 5 'end of oligonucleotides is exemplified. Can be
【0010】本発明において、溶離液は、液体クロマト
グラフィーに用いられるものであれば、特に制限されな
い。一般には、合成オリゴヌクレオチドの精製に常法と
して使用される逆相液体クロマトグラフィー(逆送HPL
C)の溶離液であり、例えば、酢酸トリエチルアンモニ
ウム等のバッファとアセトニトリル等の有機溶媒の混合
物が挙げられる。In the present invention, the eluent is not particularly limited as long as it is used for liquid chromatography. Generally, reverse-phase liquid chromatography (reverse HPLC) is commonly used for the purification of synthetic oligonucleotides.
The eluent C) includes, for example, a mixture of a buffer such as triethylammonium acetate and an organic solvent such as acetonitrile.
【0011】本発明で用いる強酸としては、例えば、塩
酸、硫酸、トリフルオロ酢酸、トリクロロ酢酸などが挙
げられる。このうち、取り扱い易さの点から、塩酸が好
ましい。The strong acid used in the present invention includes, for example, hydrochloric acid, sulfuric acid, trifluoroacetic acid, trichloroacetic acid and the like. Of these, hydrochloric acid is preferred from the viewpoint of easy handling.
【0012】本発明では、強酸を用いるため、脱保護の
反応が迅速に行われる点で優れているが、反応時間を長
くし過ぎると、オリゴヌクレオチド類のホスホジエステ
ル結合を加水分解させ、回収されるオリゴヌクレオチド
の純度を損なうことがある。したがって、強酸を溶離液
に添加した後、適当な時間を経過した後、脱保護の反応
を停止させるために、溶離液に塩基を添加して強酸を中
和することが好ましい。かかる塩基としては、重曹水、
アンモニア水、炭酸カリウム水溶液などが挙げられ、こ
れらの中でも取り扱い易さの点から、重曹水が好まし
い。脱保護に適切な反応時間は、強酸の添加量によって
異なるが、一般的には、溶離液1000容量部に対して強酸
を1規定換算の量で100容量部乃至400容量部添加するこ
とが望ましく、反応時間は、1.0乃至3.0分とすることが
望ましい。In the present invention, the use of a strong acid is excellent in that the deprotection reaction is carried out quickly, but if the reaction time is too long, the phosphodiester bond of the oligonucleotides is hydrolyzed and recovered. The purity of the oligonucleotide may be impaired. Therefore, it is preferable to neutralize the strong acid by adding a base to the eluent in order to stop the deprotection reaction after an appropriate time has elapsed after adding the strong acid to the eluent. Such bases include aqueous sodium bicarbonate,
Ammonia water, aqueous potassium carbonate solution and the like can be mentioned. Among them, aqueous sodium bicarbonate is preferred from the viewpoint of easy handling. The appropriate reaction time for deprotection varies depending on the amount of the strong acid added. In general, it is desirable to add 100 to 400 parts by volume of a strong acid in a 1N conversion amount to 1,000 parts by volume of the eluent. The reaction time is desirably 1.0 to 3.0 minutes.
【0013】[0013]
【実施例】以下、実施例に基づいて本発明をさらに詳し
く説明する。なお、本実施例で用いた材料及び測定方法
は下記のとおりである。The present invention will be described in more detail with reference to the following examples. The materials and measurement methods used in this example are as follows.
【0014】材料及び測定方法 (1)使用したオリゴDNA、脱Tr化剤、中和剤 オリゴDNAはDNA自動合成機(Expedite Model8909:日本
パーセプティブ社製)を用い、常法により、1μmolスケ
ールでTr/ON体(5′末端の水酸基がDMTr基で保護され
た状態)として合成した。担体からの切出は、常法によ
り、30%濃アンモニア水1.0mlで行った。オリゴDNAの塩
基部のアミノ基の保護基及びリン酸部の保護基の脱保護
は、常法に従い、切出後の濃アンモニア水溶液のまま耐
圧バイアルにて、50℃で1晩行った。その後、減圧乾燥
によりアンモニアを除去し、乾燥されたオリゴDNAを0.1
N−pH7.2−酢酸トリエチルアンモニウムバッファに溶解
した。なお、0.2μmol合成スケールが通常量であるた
め、合成した1/5量を粗オリゴDNAサンプルとして1回の
実験に供した。合成したオリゴDNAの配列は表1のとお
りであった。なお、表1に示すサンプルの配列表を後記
する。 Materials and Measurement Method (1) Oligo DNA, Tr Trating Agent and Neutralizing Agent Used Oligo DNA was converted to Tr on a 1 μmol scale by a conventional method using an automatic DNA synthesizer (Expedite Model 8909, manufactured by Nippon Perceptive Co.). It was synthesized as an / ON form (a state in which the hydroxyl group at the 5 'end was protected with a DMTr group). Cutting out from the carrier was carried out using 1.0 ml of 30% concentrated aqueous ammonia in a usual manner. The deprotection of the amino group protecting group and the phosphate group protecting group of the base portion of the oligo DNA was carried out at 50 ° C. overnight in a pressure-resistant vial in the form of a concentrated aqueous ammonia solution in accordance with a conventional method. Thereafter, ammonia was removed by drying under reduced pressure, and the dried oligo DNA was 0.1
Dissolved in N-pH 7.2-triethylammonium acetate buffer. Since a 0.2 μmol synthesis scale is a normal amount, one fifth of the synthesized amount was used as a crude oligo DNA sample in one experiment. Table 1 shows the sequence of the synthesized oligo DNA. The sequence listing of the samples shown in Table 1 will be described later.
【0015】[0015]
【表1】 [Table 1]
【0016】脱Tr化剤として用いる1N塩酸水は、2N塩酸
水25mlに対して滅菌水25mlを加えて攪拌して調製した。
脱Tr化反応を停止させる中和剤として用いる重曹水は、
滅菌水50mlに炭酸水素ナトリウム4.20gを溶解して調製
した。なお、滅菌水は、超純水(抵抗率10.0MΩ・cm以上
で0.2μmフィルター処理)をオートクレーブで120℃、1
5分間滅菌処理して調製した。A 1N aqueous hydrochloric acid solution used as a detrending agent was prepared by adding 25 ml of sterilized water to 25 ml of 2N hydrochloric acid solution and stirring.
A sodium bicarbonate solution used as a neutralizing agent to stop the deTr reaction is
It was prepared by dissolving 4.20 g of sodium bicarbonate in 50 ml of sterile water. The sterilized water was ultrapure water (resistivity: 10.0 MΩ · cm or more, filtered with 0.2 μm) in an autoclave at 120 ° C, 1
It was prepared by sterilizing for 5 minutes.
【0017】(2)オリゴDNA濃度測定法 オリゴDNA溶液を石英セル(光路長=10.0mm)に入れ、
分光光度計(V-550:日本分光社製)で260nmの吸光度を
測定し、その吸光度(単位:ABS)をもってDNA濃度(単
位:ODu/ml)とした。すなわち、吸光度1.0(abs)はDN
A濃度1.0(ODu/ml)に対応する。なお、上記分光光度計
の測定限界は1.8ABSであったので、オリゴDNA溶液の濃
度がこの測定限界を越える場合は、該DNA溶液を純水で
稀釈して吸光度を測定し、この吸光度に稀釈倍率を掛け
てDNA濃度を求めた。DNA量は、DNA濃度に溶液の体積を
掛けて求めた。(2) Oligo DNA concentration measurement method The oligo DNA solution is put into a quartz cell (optical path length = 10.0 mm),
The absorbance at 260 nm was measured with a spectrophotometer (V-550: manufactured by JASCO Corporation), and the absorbance (unit: ABS) was used as the DNA concentration (unit: ODu / ml). That is, absorbance 1.0 (abs) is DN
Corresponds to an A concentration of 1.0 (ODu / ml). Since the measurement limit of the above spectrophotometer was 1.8 ABS, when the concentration of the oligo DNA solution exceeded this measurement limit, the DNA solution was diluted with pure water, and the absorbance was measured. The DNA concentration was determined by multiplication. The amount of DNA was determined by multiplying the DNA concentration by the volume of the solution.
【0018】(3)脱Tr化率の測定法 本発明の方法に従って脱Tr化処理したオリゴDNAのサン
プルを、高速液体クロマトグラフィー装置(日本ウォー
ターズ社製)により脱Tr化されたオリゴDNA(Tr/ON体)
と脱Tr化されなかったオリゴDNA(Tr/OFF体)とに分離
し、両者のピークの面積を求め、下記式に従って脱Tr率
を求めた。(3) Method for Measuring DeTr-Treatment Rate A sample of the oligoDNA detrified according to the method of the present invention was treated with a high-performance liquid chromatography apparatus (manufactured by Nippon Waters Co., Ltd.) to remove the oligoDNA (Tr). / ON body)
And the oligo DNA that was not removed from Tr (Tr / OFF form), the area of both peaks was determined, and the removal rate of Tr was determined according to the following formula.
【0019】[0019]
【数1】 (Equation 1)
【0020】カラムは、C18シリカ系逆相カラム(ODSカ
ラム)であるWS-DNA(和光純薬社製)カラム(4.6mmφ
×150mm)を用いた。分析に用いるディテクタの波長は2
60nmとし、分析温度は40℃とした。グラディエントテー
ブルは、表2のとおりとした。The column is a WS-DNA (manufactured by Wako Pure Chemical Industries) column (4.6 mmφ), which is a C18 silica-based reverse phase column (ODS column).
× 150 mm). The detector wavelength used for analysis is 2
The analysis temperature was 40 ° C. The gradient table was as shown in Table 2.
【0021】なお、サンプルは、脱Tr化反応後(中和済
み)、乾燥させて1.0mlのバッファに再溶解し、その溶
液を15倍に希釈して調製した。The sample was prepared by diluting it in a 1.0 ml buffer after the Tr removal reaction (neutralized), and then diluting the solution 15-fold.
【0022】[0022]
【表2】 [Table 2]
【0023】(4)脱Tr化されたオリゴDNAの純度分析
法 脱Tr化処理によるオリゴDNA分解(ホスホジエステル結
合の加水分解)の影響を調べるために、本発明の方法に
従って脱Tr化処理したオリゴDNAのサンプルをキャピラ
リーゲル電気泳動分析により分離して純度を求めた。こ
のキャピラリーゲル電気泳動は、鎖長が1mer違うオリゴ
DNAでも、完全に異なるピークとして分離できる。分析
は、キャピラリーゲル電気泳動分析装置CAPI-3100(大
塚電子社製)を用いて行った。キャピラリーゲルカラム
は、μPAGE-5(J&W Scientific社製)を使用した。このカ
ラムの仕様は下記のとおりである: ゲル:ポリアクリルアミドゲル(5%T、5%C) バッファ:100mmol/1 トリス-ホウ酸塩、 7mol/1 尿
素(pH8.3) サイズ:75μmφ×50cm(有効長)。(4) Purity analysis method of oligo-DNA detrified In order to examine the effect of oligo-DNA degradation (hydrolysis of phosphodiester bond) by the deTr-treatment, deTr-treatment was performed according to the method of the present invention. Oligo DNA samples were separated by capillary gel electrophoresis analysis to determine purity. In this capillary gel electrophoresis, oligos with a chain length
Even DNA can be separated as completely different peaks. The analysis was performed using a capillary gel electrophoresis analyzer CAPI-3100 (manufactured by Otsuka Electronics Co., Ltd.). As a capillary gel column, μPAGE-5 (manufactured by J & W Scientific) was used. The specifications of this column are as follows: Gel: polyacrylamide gel (5% T, 5% C) Buffer: 100 mmol / 1 tris-borate, 7 mol / 1 urea (pH 8.3) Size: 75 μmφ × 50 cm (Effective length).
【0024】分析条件は下記のとおりとした: 泳動電圧:−13kV インジェクション:電圧式−10kV、2.0〜2.5秒 分析温度:25℃ ディテクタ:260nm。The analysis conditions were as follows: Electrophoresis voltage: -13 kV Injection: Voltage equation: -10 kV, 2.0 to 2.5 seconds Analysis temperature: 25 ° C. Detector: 260 nm.
【0025】なお、サンプルは、脱Tr化反応後(中和済
み)、乾燥させて1.0mlのバッファに再溶解し、2.0時間
透析した後、その溶液を15倍に希釈して調製した。[0025] The sample was prepared by diluting it in a 1.0 ml buffer after the deTr conversion reaction (neutralized), dialysis for 2.0 hours, and diluting the solution 15-fold.
【0026】実施例 上記粗オリゴDNAサンプルを高速液体クロマトグラフィ
ー装置(日本ウォーターズ社製)で精製し、Tr/ON体を
分取した。精製条件は下記のとおりであった: カラム:WS−DNA(和光純薬社製)、10mmφ×15
0mm 展開溶媒:バッファ/アセトニトリルのグラディエン
トモード バッファ=0.1N−pH7.2−酢酸トリエチルアンモニウム
(TEAA)バッファ インジェクション量:0.2μmol合成スケール相当の量 グラディエントパラメータ:表3に示すとおり。 Example The above crude oligo DNA sample was purified by a high performance liquid chromatography apparatus (manufactured by Nippon Waters), and a Tr / ON form was collected. Purification conditions were as follows: Column: WS-DNA (manufactured by Wako Pure Chemical Industries, Ltd.), 10 mmφ × 15
0 mm Developing solvent: Gradient mode of buffer / acetonitrile Buffer = 0.1 N-pH 7.2-Triethylammonium acetate (TEAA) buffer Injection amount: 0.2 μmol Synthetic scale equivalent Gradient parameters: As shown in Table 3.
【0027】[0027]
【表3】 [Table 3]
【0028】フラクションコレクターパラメータ:表
4に示すとおり。Fraction collector parameters: as shown in Table 4.
【0029】[0029]
【表4】 [Table 4]
【0030】分取したオリゴDNA(Tr/ON体)のバッファ
/アセトニトリル溶液1000μlに対して、50、100、20
0、400又は1000μlの1N塩酸水を加え、0.5、1.0、2.
0、3.0、6.0、10.0又は30.0分経過後、塩酸の2倍量に
相当する1N重曹水(中和剤)を加え、反応を停止させ
た。なお、1N塩酸水及び1N重曹水のそれぞれの添加後
10秒以内に攪拌を行った。反応時間は、1N塩酸水を
加えてから1N重曹水を加えるまでの時間に相当する。The buffered oligo DNA (Tr / ON form) in a buffer / acetonitrile solution (1000 μl) was added to 50, 100, 20
Add 0, 400 or 1000 μl of 1N aqueous hydrochloric acid and add 0.5, 1.0, 2.
After 0, 3.0, 6.0, 10.0 or 30.0 minutes, 1N aqueous sodium bicarbonate (neutralizing agent) corresponding to twice the amount of hydrochloric acid was added to stop the reaction. The stirring was performed within 10 seconds after the addition of each of the 1N hydrochloric acid solution and the 1N sodium bicarbonate solution. The reaction time corresponds to the time from the addition of 1N aqueous hydrochloric acid to the addition of 1N aqueous sodium bicarbonate.
【0031】脱Tr化処理されたオリゴDNAについて、上
記の方法に従い、脱Tr化率と純度とを測定した。その結
果を、表5及び表6に示した。With respect to the oligo DNA subjected to the DeTr treatment, the deTr ratio and the purity were measured in accordance with the above-mentioned methods. The results are shown in Tables 5 and 6.
【0032】[0032]
【表5】 [Table 5]
【0033】[0033]
【表6】 [Table 6]
【0034】表5から、Tr/ON体のHPLC分取液に直接塩
酸を添加することにより脱Tr化が行えることが示され
た。特に、該HPLC分取液1000μlに対して1N塩酸水を10
0μl以上添加し、反応時間を1.0分以上にすると好まし
いことわかった。また、表6から、該HPLC分取液1000μ
lに対する1N塩酸水の量を400μl以下とし、反応時間を
3.0分以下とした場合に、DNA鎖のホスホジエステル結合
に影響を与えることなく、高い純度を保った状態で脱Tr
化できることが示された。Table 5 shows that Tr removal can be achieved by directly adding hydrochloric acid to the HPLC fraction of the Tr / ON form. In particular, 1N aqueous hydrochloric acid was added to 1000 µl of the HPLC aliquot for 10 µl.
It was found that adding 0 μl or more and making the reaction time 1.0 minute or more is preferable. In addition, from Table 6, 1000 µL
The amount of 1N hydrochloric acid solution is set to 400 μl or less with respect to
In the case of 3.0 minutes or less, detrenching is performed while maintaining high purity without affecting the phosphodiester bond of the DNA strand.
It was shown that it can be converted.
【0035】以上から、本発明の方法においては、塩酸
水の添加量は、HPLC分取液1000容量部に対して100容量
部乃至400容量部(1N塩酸水換算)とし、反応時間は、
1.0乃至3.0分とすることが好ましいことが示された。From the above, in the method of the present invention, the amount of hydrochloric acid added was 100 to 400 parts by volume (in terms of 1N hydrochloric acid) with respect to 1,000 parts by volume of the HPLC aliquot, and the reaction time was:
It was shown that it is preferable to set the time to 1.0 to 3.0 minutes.
【0036】[0036]
【発明の効果】以上詳述のように、本発明によれば、ク
ロマトグラフィーの溶離液中のオリゴヌクレオチド類に
直接強酸を添加して、DMTr基のような疎水性保護基を脱
保護する方法が提供されたため、脱保護の前に溶離液を
除去して再溶解する従来の工程を省略することができ、
作業時間を大幅に短縮することができる。また、反応時
間の制御は、中和剤の添加により容易に行うことができ
るため、DNAの分解も容易に抑制でき、高純度のDNAを回
収することができる。As described above in detail, according to the present invention, a method for deprotecting a hydrophobic protecting group such as a DMTr group by directly adding a strong acid to oligonucleotides in a chromatography eluent. Provided, eliminating the conventional step of removing and re-dissolving the eluent prior to deprotection,
Work time can be greatly reduced. In addition, since the reaction time can be easily controlled by adding a neutralizing agent, the degradation of DNA can be easily suppressed, and high-purity DNA can be recovered.
【0037】[0037]
【配列表】 SEQUENCE LISTING <110> TOAGOSEI CO., LTD. <120> METHOD FOR DEPROTECTION OF OLIGONUCLEOTIDES <130> IDP-265 <160> 1 <210> 1 <211> 31 <212> DNA <213> Artificial Sequence <220> <223> Experimental <400> 1 gattgcctac catccgttag caactggtga t 31[Sequence List] SEQUENCE LISTING <110> TOAGOSEI CO., LTD. <120> METHOD FOR DEPROTECTION OF OLIGONUCLEOTIDES <130> IDP-265 <160> 1 <210> 1 <211> 31 <212> DNA <213> Artificial Sequence <220> <223> Experimental <400> 1 gattgcctac catccgttag caactggtga t 31
【図1】オリゴヌクレオチドの合成反応サイクルを示す
模式図である。FIG. 1 is a schematic diagram showing an oligonucleotide synthesis reaction cycle.
Claims (4)
ゴヌクレオチド類を含む液体クロマトグラフィーの溶離
液中に強酸を添加して、該オリゴヌクレオチド類の疎水
性保護基を脱離することを特徴とするオリゴヌクレオチ
ド類の脱保護方法。1. The method according to claim 1, wherein a strong acid is added to an eluent of liquid chromatography containing an oligonucleotide whose hydroxyl group is protected by a hydrophobic protecting group, and the hydrophobic protecting group of the oligonucleotide is eliminated. A method for deprotecting oligonucleotides.
は、逆相液体クロマトグラフィーから溶出されたもので
あることを特徴とする請求項1に記載の方法。2. The method according to claim 1, wherein the eluent containing the oligonucleotides has been eluted from reverse phase liquid chromatography.
酢酸及びトリクロロ酢酸からなる群から選ばれたもので
あることを特徴とする請求項1に記載の方法。3. The method according to claim 1, wherein the strong acid is selected from the group consisting of hydrochloric acid, sulfuric acid, trifluoroacetic acid and trichloroacetic acid.
させるために、塩基を前記溶離液中に添加して前記強酸
を中和することを特徴とする請求項1〜3の何れか1項
に記載の方法。4. The method according to claim 1, wherein a base is added to the eluent to neutralize the strong acid in order to stop the reaction for removing the hydrophobic protecting group. Item 2. The method according to item 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11154975A JP2000344793A (en) | 1999-06-02 | 1999-06-02 | Deprotection of oligonucleotides |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11154975A JP2000344793A (en) | 1999-06-02 | 1999-06-02 | Deprotection of oligonucleotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2000344793A true JP2000344793A (en) | 2000-12-12 |
Family
ID=15595981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11154975A Pending JP2000344793A (en) | 1999-06-02 | 1999-06-02 | Deprotection of oligonucleotides |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2000344793A (en) |
-
1999
- 1999-06-02 JP JP11154975A patent/JP2000344793A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2542453B2 (en) | Compounds useful for chemical synthesis of detectable single-stranded oligonucleotides | |
| Chow et al. | Synthesis of oligodeoxyribonucleotides on silica gel support | |
| Scaringe | RNA oligonucleotide synthesis via 5′-silyl-2′-orthoester chemistry | |
| Lönnberg | Synthesis of oligonucleotides on a soluble support | |
| JP4705716B2 (en) | Oligonucleotide deprotection | |
| JPH0359914B2 (en) | ||
| JP2001505543A (en) | Solid phase synthesis method | |
| JP2562862B2 (en) | Functional carriers for simultaneous synthesis and direct labeling of oligonucleotides as primers for template-dependent enzymatic nucleic acid synthesis | |
| JP2002511840A (en) | Liquid phase synthesis of oligonucleotides and peptides | |
| Muller et al. | Current strategies for the synthesis of RNA | |
| AU686045B2 (en) | Method for the purification of short nucleic acids | |
| Zon | Oligonucleoside phosphorothioates | |
| Hsiung et al. | Synthesis of human insulin gene. Part I. Development of reversed-phase chromatography in the modified triester method. Its application in the rapid and efficient synthesis of eight deoxyribo-oligonucleotides fragments constituting human insulin A DNA | |
| Bellon | Oligoribonucleotides with 2′‐O‐(tert‐Butyldimethylsilyl) Groups | |
| KR20230074205A (en) | Methods for preparing nucleic acid oligomers | |
| US20040044195A1 (en) | Process for separating and deprotecting oligonucleotides | |
| JP2002525288A (en) | Purification of oligomers using double end selection | |
| JP2000344793A (en) | Deprotection of oligonucleotides | |
| KR20040065994A (en) | Processes of purifying oligonucleotides | |
| US5688940A (en) | Linker for immobilization, modification and subsequent release of oligomers with a terminal hydroxyl group | |
| JP7649779B2 (en) | Method for producing nucleic acid oligomer | |
| Kuzmich et al. | Synthesis and physical characterization of the self-complementary, alternating pyrimidine/purine hexanucleotide d [CGTACG] | |
| Ferrer et al. | Synthesis of oligodeoxynucleotides containing 5-aminouracil and itsN-acetyl derivative | |
| US5808042A (en) | Detritylation of DMT-oligonucleotides using cationic ion-exchange resin | |
| Bergmann et al. | Nucleotides. Part XLIII. Solid‐phase synthesis of oligoribonucleotides using the 2‐dansylethoxycarbonyl ( 2‐{[5‐(dimethylamino) naphthalen‐1‐yl] sulfonyl} ethoxycarbonyl; dnseoc) group for 5′‐hydroxy protection |